This article summarizes the most significant insider buys and sells reported on Thursday for US stocks.
Top Insider Buys:
Camp4 Therapeutics Corp (NASDAQ:CAMP):
Northpond Ventures III, LP, a major stakeholder in Camp4 Therapeutics Corp, has significantly increased its position in the company. The firm acquired 763,636 shares at $11.00 per share, totaling approximately $8.4 million. This substantial investment demonstrates Northpond Ventures' continued confidence in the pharmaceutical company, which specializes in innovative drug development.
Bright Minds Biosciences Inc. (NASDAQ:DRUG):
Cormorant Asset Management, LP, a significant shareholder in Bright Minds Biosciences Inc., has bolstered its stake in the company. The firm and its affiliates purchased shares totaling approximately $3.2 million over a two-day period. The transactions involved multiple tranches of common shares at prices ranging from $4.53 to $25.22 per share, executed through Cormorant Global Healthcare Master Fund, LP.
Red Robin Gourmet (NASDAQ:RRGB) Burgers Inc. (NASDAQ:RRGB):
Jumana Capital Investments LLC has increased its position in Red Robin Gourmet Burgers Inc. with a series of stock purchases totaling $218,594. The transactions involved the acquisition of 37,761 shares at prices ranging from $5.5947 to $5.7936 per share. Following these purchases, Jumana Capital now holds 769,202 shares of Red Robin's common stock.
Red Robin Gourmet Burgers Inc. (NASDAQ:RRGB):
JCP Investment Partnership, LP and affiliated entities have also increased their holdings in Red Robin Gourmet Burgers Inc. The group acquired a total of 77,761 shares at prices ranging from $5.5947 to $5.7936 per share, amounting to a total investment of approximately $450,338. These purchases further solidify the group's position as a significant shareholder, collectively holding more than 10% of Red Robin's outstanding shares.
Upstream Bio, Inc. (NASDAQ:UPB):
OrbiMed Advisors LLC, a prominent shareholder in Upstream Bio, Inc., has substantially increased its stake in the company. The firm acquired 825,000 shares at $17 per share, totaling $14,025,000. This significant investment demonstrates OrbiMed's continued confidence in the pharmaceutical company.
Top Insider Sells:
Cloudflare, Inc. (NYSE:NYSE:NET):
Matthew Prince, CEO and Chair of the Board at Cloudflare, Inc., reported significant stock sales totaling approximately $14.5 million. Prince sold 126,152 shares of Class A Common Stock at prices ranging from $90.6366 to $94.7571 per share. These transactions were executed under a pre-established Rule 10b5-1 trading plan.
Carvana Co. (NYSE:NYSE:CVNA):
Ernest C. Garcia II, a significant shareholder of Carvana Co., sold shares of the company's Class A Common Stock amounting to approximately $38.5 million. The transactions occurred at prices ranging from $189.41 to $194.82 per share, conducted under a Rule 10b5-1 trading plan adopted earlier this year.
Squarespace, Inc. (NYSE:SQSP):
Andrew Braccia, a director at Squarespace, Inc., reported substantial stock sales totaling approximately $647.7 million. Braccia sold 13,929,575 shares of Class A Common Stock at $46.50 per share as part of a broader arrangement related to a merger agreement involving Squarespace and Spaceship Purchaser, Inc.
Charles Schwab Corp. (NYSE:NYSE:SCHW):
Charles R. Schwab, Co-Chairman of Charles Schwab Corp., executed a notable stock transaction involving the sale of 62,345 shares at an average price of $72.52 per share, totaling approximately $4.5 million. Schwab also acquired the same number of shares through the exercise of a nonqualified stock option at $28.44 per share.
Signet Jewelers Ltd. (NYSE:NYSE:SIG):
Virginia Drosos, CEO of Signet Jewelers Ltd., sold 49,000 shares over two days, totaling approximately $5.1 million. The shares were sold at prices ranging from $101.25 to $102.34 per share under a Rule 10b5-1 trading plan established in June 2024.
Staying informed about insider trading activity is crucial for investors as it can provide valuable insights into a company's financial health and future prospects. While insider buying often signals confidence in the company's outlook, insider selling may have various motivations and should be interpreted cautiously. Always consider these transactions as part of a broader investment strategy and conduct thorough research before making investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.